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T2; and N stage was: 25 Nx, 65 N0, 26 N1, 1 N3. Mastectomy 
was performed in 17 and wide local excision in 100. Axillary 
dissection was done in 67 and sentinel node dissection in 33 
with a median number of 13 (1-24) lymph nodes excised. 52 
received chemotherapy and 72 endocrine therapy. All 
received radiotherapy (1 neo- and 116 adjuvant) with 67 
breast/chest wall alone and 40 breast/chest wall and 
regional nodal irradiation. The median time to onset of LE 
from the completion of radiotherapy was 0.5 y (0.1 to 7.8). 
LEs included: 38 truncal and/or breast pain; 24 arm 
lymphedema; 16 breast inflammation; 16 breast 
lymphedema; 14 neck, truncal, breast fibrosis; 9 tissue 
ulcer/necrosis; 2 brachial plexopathy 2; and 11 other. 
Following LE consultation, 90 received pharmacologic (18 
anti-inflammatory, 60 anti-oxidant, 12 pentoxifylline or 4 
other) and/or non-pharmacologic management (33 self-
lymphatic massage). Transient mild toxicities were observed 
in 8 (9%) (4 GI, 2 MSK, 2 pre-syncope). No major toxicities 
from LE treatment occurred. Moderate to significant 
improvement was observed in 78 (87%) with12 patients 
demonstrating no improvement. 
Conclusions: Following completion of therapy, acute 
toxicities may persistent or late toxicities arise. For women 
with these toxicities, current interventions appear to have a 
meaningful impact upon LE's with minimal side effects. 
Recognition of the potential to manage persistent acute 
effects and LE's is important and needs to be better 
incorporated within breast cancer survivorship to best 
improve aftercare. 
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Purpose/Objective: Survivors of Hodgkin lymphoma (HL) and 
subgroups of non-Hodgkin lymphoma (NHL) are at increased 
risk of various late adverse effects of radiotherapy and 
chemotherapy, leading to substantial excess morbidity and 
mortality. The need for long-term follow-up is increasingly 
recognized. Long-term follow-up care programmes have been 
established for childhood cancer survivors, but not yet for 
(N)HL survivors. Therefore, the Dutch BETER consortium 
(Better care after Hodgkin lymphoma: Evaluation of long-
term Treatment Effects and screening Recommendations) has 
developed a nationwide infrastructure for survivorship care 
clinics for survivors of HL and subgroups of non-Hodgkin 
lymphoma (diffuse large B-cell lymphoma). The consortium 
aims to: 1) establish evidence-based follow-up guidelines for 
(N)HL survivors; 2) identify and trace survivors eligible for 
follow-up care; 3) educate survivors about possible late 
adverse effects of treatment; and 4) provide risk-based care 
and advice regarding prevention. 
Materials and Methods: Follow-up guidelines were developed 
according to international standards. The guideline 
development group consisted of clinicians, methodological 
experts and patient representatives. We developed guidelines 
for second malignancies, cardiovascular disease, thyroid 
disease and osteoporosis after premature menopause. 
Recommendations are given for fertility care and family 
planning, therapy for neck muscle weakness, and infection 
prophylaxis for functional asplenia. 
Results: We are currently identifying and tracing a cohort of 
approximately 8,500 HL survivors and 3,000 NHL survivors in 
22 hospitals throughout the Netherlands, including all 
radiotherapy centres. Eligible patients for follow-up care 
survived for ≥5 years and were treated at ages 15-70 years 
from 1970 onwards. Survivors are identified through the 
Netherlands Cancer Registry, the nationwide pathology 
registry and hospital-based registries. Tracing of current 
addresses of survivors is done through the nationwide 
Netherlands Personal Records Database. For all survivors, 
treatment data are collected from medical records to provide 
risk-based screening recommendations. The website 
www.beternahodgkin.nl was developed to inform and 
educate survivors about late effects. Currently, a survivorship 
care plan is being developed. A nationwide database, 
including screening and adverse events data, is being 
developed to evaluate the follow-up guidelines for diagnostic 
value and efficacy. 
Conclusions: We expect that the BETTER project will 
improve healthy life expectancy and quality of life for (N)HL 
survivors. Evaluation of follow-up care will lead to improved 
knowledge regarding the diagnostic value and efficacy of the 
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proposed screening methods, contributing to more evidence-
based follow-up programmes.  
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Purpose/Objective: This work presents a Monte Carlo 
method for calculating the factors required to perform 
reference dosimetry in a water phantom for two different 
designs of 192Ir Brachytherapy source used in the UK. The UK 
code of practice is an air-kerma based code however one 
sometimes wishes to perform reference dosimetry in a water 
phantom. We present a Monte Carlo calculation of the factors 
required to perform such measurements with an air-kerma 
calibration code. We present results with a thimble chamber 
calibrated at 10 cm with measurements at 2 cm in a water 
phantom. 
Materials and Methods: The Geant 4 framework (Agnostelli 
et al.) was used to produce a simulation of an 192Ir HDR 
Nucletron v2 microselectron source and a Varian Varisource. 
In the simulation the type of source and the position of the 
source relative to the chamber are definable at run-time. 
The source position is also a run-time definable quantity and 
so line sources can be created as a superposition of different 
source positions. The radioactive decay libraries in Geant 4 
were used to simulate the decay chain. A single calibration 
factor kch can be determined from a series of four simulations 
as shown in (Ma and Nahum, 1993), where Dw = MNkkch, Dw is 
the dose to water, M is the measured value and Nk the 
calibration factor. Alternatively kch can be calculated as the 
product of a series of factors (Reynaert et al. 1998). In this 
case kch is the product of stem and perturbation factors as 
well as a gradient correction, a correction for electron 
contamination due to high energy electrons from outside of 
the chamber and an angular response factor. 
Results: There was very little difference between the energy 
fluence spectra between the sources. The spectrum of the 
Nucletron source is slightly harder in air although this is not 
seen in water. Many of our factors can be broadly compared 
with those in Reynaert et al. for verification. At a distance of 
2 cm we found the gradient factor to be 1.11 for the 
Nucletron source, Reynaert et al. found this value to be 
1.077 at 2.5 cm and 1.36 and 1 cm. The fraction of dose 
deposited in the sensitive volume due to electrons from 
outside of the chamber is 1.5% at 2 cm in this study and 1.4% 
at 2.5 cm in Reynaert et al. The ratio (µen/ρ)w/air evaluated in 
water at cm is 1.100 for both Nucletron and Varian sources. 
For both sources this value is 1.109 at 2 cm in air. The 
product of the perturbation factor and the stem factor is 
1.019, with the Varian source this was increased slightly to 
1.028.  
Conclusions: Monte Carlo provides a method for performing 
reference dosimetry for tasks such as audits using non-
standard reference conditions. This can be done either by 
calculating factors required to calculate dose from an air 
kerma calibration or by direct Monte Carlo calculation of Nk 
from the dose deposited in the chamber. Having produced 
results broadly in agreement with previous work we are 
conducting experiments to verify our simulation more 
accurately. 
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Purpose/Objective: To study the behavior of the new 
SourceCheck 4Pi ionization chamber with the air density for 
low energy brachytherapy sources of I-125. 
Materials and Methods: Three PTW SourceCheck 4Pi 
chambers TW33005 were used with one electrometer PTW 
Unidos. As source, a I-125 selectSeed seed, manufactured by 
Isotron with an nominal air-kerma strength value of SK = 
0.610 cGy cm2/h was used. Barometer-thermometer-
hygrometer PCE_THB 40 was used inside a home-made 
pressurized chamber controlled by a vacuum pump. 
The direct measurements of the source used in this study 
must be corrected, according to our previous study of the 
preceding model of the SourceCheck chamber, with the 
following equation [1]: 
 
where there are two correction factors that depend on the 
air density.  
The first one is: 
 
that is actually the usual density correction factor, but 
explicitly written as a function of the air density inside the 
chamber, ρ, and the density of that air in normal conditions 
(P0=1013.25 hPa, T=293.15 K), ρ0. 
The second factor is an additional one that shows up as 
consequence of the combination of two facts: On one hand 
the range of the secondary electrons produced by the I-125 is 
of the order of the dimensions of the active volume, and 
therefore, the Bragg-Gray theory does not hold; and on the 
other hand, the chamber materials influence the 
measurement. As shown in [1]: 
 
Results: In the Figure, the results of the measurements for 
the I-125 made in the pressurized chamber are shown for 
different densities once they have been normalized and 
corrected by the pressure-temperature usual factor. The fits 
of Eq. (2) to these experimental data are also shown. The 
most relevant results are, firstly, the linear behavior of this 
dependence, and secondly, the coincidence, within the 
uncertainties, of the three chambers as far as their air 
density dependence is concerned. All uncertainties are 
associated to a coverage factor k=2. 
Figure also shows the air density dependence as described for 
the HDR1000 Plus chamber [2] fitted by means of the 
equation (2), instead of use the potential model of Griffin et 
al. [2]. The air density dependence for the chambers 
SourceCheck 4Pi and HDR1000 Plus follows the same trend, 
that is, they have the same direction, being nevertheless 
somehow smaller for the former. 
